Fate Of Speedel’s Diabetic Nephropathy Drug May Be Clearer Mid-Year 2007
This article was originally published in The Pink Sheet Daily
Executive Summary
DSMB halts Phase III trial of SPP301 due to an imbalance of fluid retention in patients in the study arms.
You may also be interested in...
Big Pharma Has Eye On Pharmacopeia’s DARA For Blood Pressure
DARA, a first-in-class dual-acting angiotensin and endothelin receptor antagonist in development for hypertension and diabetic nephropathy, is in Phase II development.
Big Pharma Has Eye On Pharmacopeia’s DARA For Blood Pressure
DARA, a first-in-class dual-acting angiotensin and endothelin receptor antagonist in development for hypertension and diabetic nephropathy, is in Phase II development.
Speedel CEO Alice Huxley: An Interview With “The Pink Sheet” DAILY (Part 2 of 2)
Exec discusses Speedel’s other mid-stage pipeline candidates, the firm’s relationship with Novartis and business development going forward.